

Florence F Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1907378/publications.pdf>

Version: 2024-02-01

18
papers

1,063
citations

643344

15
h-index

939365

18
g-index

21
all docs

21
docs citations

21
times ranked

2446
citing authors

#	ARTICLE	IF	CITATIONS
1	Multigram Preparation of BRD4780 Enantiomers and Assignment of Absolute Stereochemistry. <i>Journal of Organic Chemistry</i> , 2021, 86, 4281-4289.	1.7	2
2	GSK3 β , not GSK3 γ , drives hippocampal NMDAR-dependent LTD via tau-mediated spine anchoring. <i>EMBO Journal</i> , 2021, 40, e105513.	3.5	75
3	Roles of glycogen synthase kinase 3 alpha and calcineurin in regulating the ability of sperm to fertilize eggs. <i>FASEB Journal</i> , 2020, 34, 1247-1269.	0.2	9
4	Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. <i>Cancer Discovery</i> , 2020, 10, 1690-1705.	7.7	38
5	Selective inhibition of glycogen synthase kinase 3 β corrects pathophysiology in a mouse model of fragile X syndrome. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	42
6	Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. <i>Cell</i> , 2019, 178, 521-535.e23.	13.5	124
7	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. <i>Cancer Cell</i> , 2019, 35, 664-676.e7.	7.7	70
8	Glycogen synthase kinase 3 β inhibition induces lymphangiogenesis through β -catenin-dependent and mTOR-independent pathways. <i>PLoS ONE</i> , 2019, 14, e0213831.	1.1	9
9	Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	69
10	Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4008-4015.	1.4	51
11	Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. <i>ACS Chemical Biology</i> , 2016, 11, 1952-1963.	1.6	55
12	Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e102684.	1.1	65
13	Small Molecule Inhibitors of Zinc-dependent Histone Deacetylases. <i>Neurotherapeutics</i> , 2013, 10, 589-604.	2.1	81
14	Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia. <i>Future Medicinal Chemistry</i> , 2013, 5, 1491-1508.	1.1	34
15	Class I HDAC imaging using [³ H]CI-994 autoradiography. <i>Epigenetics</i> , 2013, 8, 756-764.	1.3	28
16	A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests. <i>PLoS ONE</i> , 2013, 8, e71323.	1.1	118
17	Inhibition of Histone Deacetylase 3 Protects Beta Cells from Cytokine-Induced Apoptosis. <i>Chemistry and Biology</i> , 2012, 19, 669-673.	6.2	85
18	AKT Kinase Activity Is Required for Lithium to Modulate Mood-Related Behaviors in Mice. <i>Neuropsychopharmacology</i> , 2011, 36, 1397-1411.	2.8	98